Halozyme Therapeutics
HALOAlgoritmens signaler
- ›Starkt 3m-momentum (+59.1%)
- ›Starkt 6m-momentum (+104.7%)
- ›Starkt 12m-momentum (+97.7%)
- ›Pris över MA50 och MA200 (uppåttrend)
- ›Hög volatilitet (47% årlig)
- ›+114% från 52v-botten
📰 Senaste nyheter & analys
Källor: Placera, Nyhetsbyrån Direkt, Google NewsHalozyme Therapeutics, Inc. (HALO) Stock Price, News, Quote & History - Yahoo! Finance Canada
1 d sedanHalozyme Therapeutics, Inc. (HALO) Stock Price, News, Quote & History Yahoo! Finance Canada
Yahoo! Finance CanadaHALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards? - Yahoo Finance
1 d sedanHALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards? Yahoo Finance
Yahoo FinanceHalozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
2 d sedanHalozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth Yahoo Finance
Yahoo FinanceHalozyme Therapeutics, Inc. (HALO) Stock Forecasts - Yahoo Finance
3 d sedanHalozyme Therapeutics, Inc. (HALO) Stock Forecasts Yahoo Finance
Yahoo FinanceWhat Did Halozyme Stock Investors Miss Before The Run? - Trefis
4 d sedanWhat Did Halozyme Stock Investors Miss Before The Run? Trefis
TrefisStrong Royalties and New Launches Accelerate Halozyme Therapeutics’ (HALO) Growth Momentum - Yahoo Finance
4 d sedanStrong Royalties and New Launches Accelerate Halozyme Therapeutics’ (HALO) Growth Momentum Yahoo Finance
Yahoo FinanceHalozyme to Report Third Quarter 2026 Financial and Operating Results
2026-10-22Halozyme to Report Third Quarter 2026 Financial and Operating Results PR Newswire SAN DIEGO, Oct. 22, 2026 SAN DIEGO , Oct. 22, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Hal
Halozyme TherapeuticsPR NewswireHalozyme Therapeutics Stock: 6 Straight Green Days, Up 14% - Trefis
2026-10-22Halozyme Therapeutics Stock: 6 Straight Green Days, Up 14% Trefis
TrefisWill Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
2026-10-13Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report? Yahoo Finance
Yahoo FinanceHalozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets
2026-10-07Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets PR Newswire SAN DIEGO, Oct. 7, 2026 SAN DIEGO , Oct. 7, 2026 /PRNewswire/ -- Halozyme Ther
Halozyme TherapeuticsPR NewswireHalozyme Announces Appointment of Jim Daly to its Board of Directors
2026-09-30Halozyme Announces Appointment of Jim Daly to its Board of Directors PR Newswire SAN DIEGO, Sept. 30, 2026 SAN DIEGO , Sept. 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Ha
Halozyme TherapeuticsPR NewswireHalozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
2026-09-18Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 PR Newswire SAN DIEGO, Sept. 17, 2026 SAN DIEGO , Sept. 17, 2026 /PRNe
Halozyme TherapeuticsPR NewswireHalozyme to Participate at Upcoming Investor Conferences
2026-09-02Halozyme to Participate at Upcoming Investor Conferences PR Newswire SAN DIEGO, Sept. 2, 2026 SAN DIEGO , Sept. 2, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today
Halozyme TherapeuticsPR NewswireHalozyme Appoints Dannielle Appelhans to its Board of Directors
2026-08-18Halozyme Appoints Dannielle Appelhans to its Board of Directors PR Newswire SAN DIEGO, Aug. 18, 2026 SAN DIEGO , Aug. 18, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme"
Halozyme TherapeuticsPR NewswireHalozyme to Report Second Quarter 2026 Financial and Operating Results
2026-07-23Halozyme to Report Second Quarter 2026 Financial and Operating Results PR Newswire SAN DIEGO, July 23, 2026 SAN DIEGO , July 23, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Ha
Halozyme TherapeuticsPR NewswireHalozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
2026-07-20Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology PR Newswire SAN DIEGO, Jul
Halozyme TherapeuticsPR Newswire
Klicket på "Köp i Nordnet" öppnar din Nordnet-app om installerad — där loggar du in med BankID. Annars öppnas Nordnets webbsajt där du kan logga in med BankID på samma sätt.